- In an update to investors, Rhythm Pharmaceuticals (NASDAQ:RYTM) says it expects to initiate a Phase 3 clinical trial this year evaluating setmelanotide in patients with Bardet-Biedl syndrome. Other 2018 setmelanotide-related milestones:
- Initial data from Phase 2 proof-of-concept study in patients with Alström syndrome, POMC epigenetic disorders and POMC heterozygous deficiency obesity.
- Enrollment in a Phase 3 study in POMC (proopiomelanocortin) deficiency to be completed next quarter, preliminary data expected in H1 2019 followed by a U.S. marketing application.
- Enrollment in Phase 3 study in LEPR deficiency obesity to be completed by year-end.
- The company expects its current level of quick assets to fund operations into H2 2019.